GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Notes Receivable

ProKidney (MEX:PROK) Notes Receivable : MXN0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney Notes Receivable?

ProKidney's Notes Receivable for the quarter that ended in Mar. 2024 was MXN0.00 Mil.


ProKidney Notes Receivable Historical Data

The historical data trend for ProKidney's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Notes Receivable Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - -

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ProKidney Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


ProKidney Notes Receivable Related Terms

Thank you for viewing the detailed overview of ProKidney's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (MEX:PROK) Business Description

Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.